trial summary · NCT07725406
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies
Trial record from the TrialBase DB dataset, status RECRUITING, condition Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Weill Medical College of Cornell University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.
Source record: https://clinicaltrials.gov/study/NCT07725406
Facts
| registry id | NCT07725406 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) |
| sponsor | Weill Medical College of Cornell University |
| sponsor class | OTHER |
| enrollment | 32 |
| start date | 2026-11 |
| primary completion | 2028-08-01 |
| completion | 2033-08-31 |
| results posted | not reported |
Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed or Refractory Multiple Myeloma (MM)
Interventions
- Lymphodepleting chemotherapy: Cyclophosphamide
- Lymphodepleting chemotherapy: Bendamustine
- Lymphodepleting chemotherapy: Fludarabine
- Lisocabtagene Maraleucel
- Axicabtagene Ciloleucel
- Ciltacabtagene Autoleucel
- Low-Dose Total Body Irradiation
Countries
- United States
Intervention types: DRUG, OTHER, RADIATION
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.